Login / Signup

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment.

Robert A HauserAntonella FavitL Arthur HewittAnnika LindstenStephen GornySteven KymesStuart H Isaacson
Published in: Neurology and therapy (2022)
NCT02586623.
Keyphrases
  • open label
  • spinal cord injury
  • clinical trial
  • study protocol
  • phase ii
  • squamous cell carcinoma
  • randomized controlled trial
  • phase ii study